Anti-p53 Antibody detects endogenous levels of total p53 protein.
TP53 gene is mapped to human chromosome 17p13.1.
Immunogen
The antiserum was produced against synthesized peptide derived from human p53.
Immunogen Range: 344-393
Biochem/physiol Actions
TP53 gene is involved in the regulation of cell cycle, senescence and apoptosis upon oncogene activation, stress and DNA damage. Therefore, the gene has anti-tumor activity initiation and prevents tumor progression. Mutation in TP53 is known to be the major cause of almost half of all human malignancy. Breast cancer is one such condition in which, the disease development is severe due to mutation in TP53 gene.
Features and Benefits
Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.
Physical form
Rabbit IgG in phosphate buffered saline (without Mg2+ and Ca2+), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Systemic metastasis is the major cause of death from melanoma, the most lethal form of skin cancer. Although most patients with melanoma exhibit a substantial gap between onset of primary and metastatic tumors, signaling mechanisms implicated in the period of
Wip1 phosphatase: between p53 and MAPK kinases pathways
Goloudina, AR
Oncotarget, 7(21), 31563?31571-31563?31571 (2016)
Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity
Sriraman A
Oncotarget, 7(22), 31623?31638-31623?31638 (2016)
Reprogramming pancreatic stellate cells via p53 activation: A putative target for pancreatic cancer therapy
Ridinger MS
PLoS ONE, 12(12), 1-22 (2017)
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
Fountzilas
Oncotarget, 7(22), 32731?3275-32731?3275 (2016)
Questions
Reviews
★★★★★ No rating value
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
